Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 6 | 1 | 4 | 0 | 0 |
Analyst Firms Making Recommendations1
- Jefferies
- Wedbush
- HC Wainwright & Co.
- Piper Sandler
- Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kinnate Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | -9.91% | Jefferies | Roger Song | $31 → $2 | Maintains | Buy | Get Alert |
| 09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | -9.91% | Wedbush | David Nierengarten | $14 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
| 09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 80.18% | Piper Sandler | Christopher Raymond | $20 → $4 | Downgrade | Overweight → Neutral | Get Alert |
| 08/15/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 981.08% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 981.08% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
| 05/18/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 981.08% | HC Wainwright & Co. | Robert Burns | $25 → $24 | Maintains | Buy | Get Alert |
| 05/12/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 530.63% | Wedbush | David Nierengarten | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 143.24% | Stifel | Benjamin Burnett | $5 → $5.4 | Maintains | Hold | Get Alert |
| 04/20/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1026.13% | HC Wainwright & Co. | Robert Burns | $33 → $25 | Maintains | Buy | Get Alert |
| 04/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1071.17% | Goldman Sachs | Paul Choi | $29 → $26 | Maintains | Buy | Get Alert |
| 04/18/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1071.17% | Goldman Sachs | Paul Choi | $29 → $26 | Maintains | Buy | Get Alert |
| 03/20/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1386.49% | HC Wainwright & Co. | Robert Burns | → $33 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 260.36% | Stifel | Benjamin Burnett | $11 → $8 | Maintains | Hold | Get Alert |
| 03/16/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1026.13% | Wedbush | David Nierengarten | $29 → $25 | Maintains | Outperform | Get Alert |
| 11/17/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 395.5% | Stifel | Benjamin Burnett | $35 → $11 | Downgrade | Buy → Hold | Get Alert |
| 07/28/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1386.49% | HC Wainwright & Co. | Robert Burns | → $33 | Initiates | → Buy | Get Alert |
| 05/24/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1206.31% | Goldman Sachs | — | $44 → $29 | Maintains | Buy | Get Alert |
| 05/19/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.22 | 1251.35% | Piper Sandler | Christopher Raymond | $52 → $30 | Maintains | Overweight | Get Alert |
What is the target price for Kinnate Biopharma (KNTE)?
The latest price target for Kinnate Biopharma (NASDAQ: KNTE) was reported by Jefferies on September 19, 2023. The analyst firm set a price target for $2.00 expecting KNTE to fall to within 12 months (a possible -9.91% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kinnate Biopharma (KNTE)?
The latest analyst rating for Kinnate Biopharma (NASDAQ: KNTE) was provided by Jefferies, and Kinnate Biopharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Kinnate Biopharma (KNTE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kinnate Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kinnate Biopharma was filed on September 19, 2023 so you should expect the next rating to be made available sometime around September 19, 2024.
Is the Analyst Rating Kinnate Biopharma (KNTE) correct?
While ratings are subjective and will change, the latest Kinnate Biopharma (KNTE) rating was a maintained with a price target of $31.00 to $2.00. The current price Kinnate Biopharma (KNTE) is trading at is $2.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.